Advances in Acute Stroke Treatment 2020

Authors and Disclosures

Joseph P. Broderick, MD and Michael D. Hill , MD, MSc, FRCPC

Department of Neurology, University of Cincinnati Gairdner Neuroscience Institute, University of Cincinnati Academic Health Center, OH (J.P.H.). Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary and Foothills Medical Centre, Alberta, Canada (M.D.H.).

Correspondence to
Michael D. Hill, Department of Clinical Neuroscience & Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary & Foothills Medical Center, HBA 2939, Health Science Centre, 3330 Hospital Dr NW, Calgary, AB T2N4N1, Canada. Email michael.hill@ucalgary.ca

Disclosures
Dr Broderick reports funding from the National Institutes of Health (National Institute of Neurological Disorders and Stroke and National Heart, Lung, and Blood Institute) and other support from Genentech during the conduct of the study; other support from Ono Pharmaceuticals and other support from Novo Nordisk outside the submitted work. Dr Hill reports grants from NoNo Inc, grants from Canadian Institutes for Health Research, grants from Medtronic LLC, and grants from Boehringer Ingelheim Canada Ltd outside the submitted work; in addition, Dr Hill has a patent to US Patent office number: 62/086,077 issued and licensed; and Director at Circle NVI; Director at the Canadian Stroke Consortium; Director and the Canadian Neuroscience Federation.